Radioiodine and thyroid disease: the beginning*,**

https://doi.org/10.1016/S0001-2998(96)80020-1Get rights and content

In 1936, Karl Compton, then president of the Massachusetts Insitute of Technology (MIT) and the thyroid group of the Massachusetts General Hospital (MGH), undertook a joint study that led to the production of small amounts of short-lived radioiodine (iodine 128, half-life, 25 min). The original intent was to use it for diagnosis and treatment of thyroid disease, but in order to explore the underlying physiology, their first work was performed in rabbits and published in 1938. It clearly showed that the radioiodine was selectively and avidly taken up by the thyroid gland. It was immediately apparent to the MGH-MIT group and another team working at the Berkeley, CA cyclotron that longer-lasting iodine isotopes were needed, and soon both developed procedures for cyclotron-produced 130I (half-life, 12.5 hr) and 131I (half-life, 8 d). In 1939, the Berkeley group, using 131I, was the first to show that the normal human thyroid gland accumulated radioiodine. By 1941, the MGH-MIT team, using mainly 130I, was able to successfully treat a few patients with hyperthyroidism, and so achieved their original goal. The Berkeley group did the same a few months later, using mainly 131I. Both presented results at the same meeting of the American Society for Clinical Investigation in Atlantic City, NJ in the spring of 1942. This was in the midst of World War II and it was not easy to get much 130I or 131I, so experience was limited. Although effective, radioiodine treatment of hyperthyroidism had not been widely adopted by the end of the war in 1945, partly because radioiodine remained in short supply and partly because another medical therapy for hyperthyroidism, antithyroid drugs, had been invented. However, by 1946, fission-derived radioiodine became readily available as a by-product of the Manhattan project in Oak Ridge, TN; hundreds of patients were treated within a few years, both for hyperthyroidism and for thyroid cancer. A new treatment, based on the physiological application of a radioisotope of iodine, was then a reality.

References (33)

  • MillerEH et al.

    Treatment of Graves' disease with radioiodine

    Am J Med

    (1948)
  • MeansJH

    Historical background of radioiodine in medicine

    N Engl J Med

    (1955)
  • EvansRD

    Early history (1936–1946) of nuclear medicine in thyroid studies at Massachusetts General Hospital

    Med Phys

    (1975)
  • StanburyJ
  • ComptonK

    Letter to S Hertz,

  • JoliotF et al.

    Artificial production of a new kind of radio-element

    Nature

    (1934)
  • FermiE

    Radioactivity induced by neutron bombardment

    Nature

    (1934)
  • HertzS et al.

    Radioactive iodine as an indicator in the study of thyroid physiology

    Proc Soc Exp Biol Med

    (1938)
  • Evans R: Personal communication,...
  • HertzS et al.

    Radioactive iodine as an indicator in thyroid physiology. II. Iodine collection by normal and hyperplastic glands in rabbits

    Am J Physiol

    (1940)
  • Del RegatoJA

    Jean Frederic Joliot

    Int J Radiat Oncol Biol Phys

    (1935)
  • HamiltonJG

    The rates of absorption of the radioactive isotopes of sodium, potassium, chlorine, bromine, and iodine in normal human subjects

    Am J Physiol

    (1938)
  • TapeGF et al.

    Induced radioactivity in tellurium

    Physical Rev

    (1938)
  • Seaborg GT: Personal communication,...
  • LivingoodJJ et al.

    Radioactive iodine isotopes

    Phys Rev

    (1938)
  • HamiltonJG et al.

    Studies in iodine metabolism by the use of a new radioactive isotope of iodine

    Am J Physiol

    (1939)
  • Cited by (86)

    • 2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease

      2022, Endocrinology and Metabolism Clinics of North America
      Citation Excerpt :

      ATDs should be discontinued if transaminase levels are more than 3 times the upper limit of normal or if the transaminitis worsens.7 RAI has been a safe and effective treatment option for hyperthyroidism for more than 8 decades.22 RAI is well-tolerated and has few associated adverse effects in treatment doses for GD.7

    • Nuclear medicine therapy of thyroid goiter

      2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
    • Paediatric Molecular Radiotherapy: Challenges and Opportunities

      2021, Clinical Oncology
      Citation Excerpt :

      Images of appropriate facilities in an age-appropriate environment are shown in Figure 4. The use of radioactive isotopes of iodine for thyroid diseases started over 75 years ago [23]. The dose schedules used for 131I ablation and therapy for differentiated thyroid cancer were developed empirically.

    View all citing articles on Scopus
    *

    Supported by the Thyroid Research Fund, Division of Nuclear Medicine, New York, NY (Dr Becker); and an unrestricted grant from Daniels Pharmaceuticals, Inc, St. Petersburg, FL (Dr Sawin).

    **

    Presented in part as the Presidential Address, American Thyroid Association, held in New Orleans, LA, October 7, 1983 (Dr Becker).

    View full text